GlassScriptPrepare for your visit
Stanislav Goykhman
Endocrinology, Diabetes & Metabolism · Lyndhurst, NJ · NPI 1740488402
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$278,450.21
in general payments reported to CMS, 2019-2025 · $57K in 2025
The $57K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Who reported paying
General payments only, top 6 by amount.
- Boehringer Ingelheim Pharmaceuticals, INC. $79,472.87
- Lilly USA, LLC $71,458.20
- Dexcom, INC. $42,983.31
- Astrazeneca Pharmaceuticals LP $42,285.61
- Amarin Pharma, INC. $21,183.37
- Merck Sharp & Dohme LLC $4,512.19
Drugs and devices associated with these payments
Zepbound Dexcom G7 Gss (161) Jardiance Dexcom Stelo Glucose Biosensor Mounjaro Dexcom G6 Transmitter Korlym Ozempic Farxiga Omnipod Tzield Rybelsus
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Stanislav Goykhman listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/125107/stanislav-goykhman